PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
NASDAQ:PRVA - Nasdaq - US74276R1023 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to PRVA. PRVA was compared to 102 industry peers in the Health Care Providers & Services industry. While PRVA has a great health rating, there are worries on its profitability. PRVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PRVA was profitable.
In the past year PRVA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
In the past 5 years PRVA always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of PRVA (1.32%) is comparable to the rest of the industry.
PRVA has a Return On Equity (2.37%) which is comparable to the rest of the industry.
PRVA has a Return On Invested Capital (2.00%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROIC | 2% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PRVA (0.87%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of PRVA has declined.
PRVA has a Operating Margin (1.19%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of PRVA has declined.
Looking at the Gross Margin, with a value of 10.09%, PRVA is doing worse than 75.49% of the companies in the same industry.
PRVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
Compared to 1 year ago, PRVA has more shares outstanding
The number of shares outstanding for PRVA has been increased compared to 5 years ago.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.98 indicates that PRVA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.98, PRVA belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.98 |
ROIC/WACC0.22
WACC9.04%
2.3 Liquidity
PRVA has a Current Ratio of 1.88. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.88, PRVA is doing good in the industry, outperforming 71.57% of the companies in the same industry.
PRVA has a Quick Ratio of 1.88. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
PRVA has a Quick ratio of 1.88. This is in the better half of the industry: PRVA outperforms 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
PRVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.00%.
The Earnings Per Share has been growing slightly by 7.43% on average over the past years.
The Revenue has been growing slightly by 6.79% in the past year.
The Revenue has been growing by 17.17% on average over the past years. This is quite good.
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.59% yearly.
The Revenue is expected to decrease by -0.38% on average over the next years.
EPS Next Y92.08%
EPS Next 2Y96.51%
EPS Next 3Y61.59%
EPS Next 5YN/A
Revenue Next Year11.83%
Revenue Next 2Y11.13%
Revenue Next 3Y11.67%
Revenue Next 5Y-0.38%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 190.00, the valuation of PRVA can be described as expensive.
PRVA's Price/Earnings is on the same level as the industry average.
PRVA is valuated expensively when we compare the Price/Earnings ratio to 26.30, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 53.67, the valuation of PRVA can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as PRVA.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.06, PRVA is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 190 | ||
| Fwd PE | 53.67 |
4.2 Price Multiples
61.76% of the companies in the same industry are cheaper than PRVA, based on the Enterprise Value to EBITDA ratio.
PRVA's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PRVA is cheaper than 60.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.49 | ||
| EV/EBITDA | 80.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PRVA does not grow enough to justify the current Price/Earnings ratio.
PRVA's earnings are expected to grow with 61.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.06
PEG (5Y)25.56
EPS Next 2Y96.51%
EPS Next 3Y61.59%
5. Dividend
5.1 Amount
PRVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.8
-0.21 (-0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.73%
Inst Owner Change1.52%
Ins Owners6.04%
Ins Owner Change0.88%
Market Cap2.78B
Analysts84.29
Price Target30.19 (32.41%)
Short Float %3.13%
Short Ratio4.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.31%
Min EPS beat(2)-40.79%
Max EPS beat(2)-37.83%
EPS beat(4)0
Avg EPS beat(4)-38.4%
Min EPS beat(4)-40.79%
Max EPS beat(4)-36.27%
EPS beat(8)1
Avg EPS beat(8)-32.84%
EPS beat(12)5
Avg EPS beat(12)107.25%
EPS beat(16)8
Avg EPS beat(16)62.22%
Revenue beat(2)2
Avg Revenue beat(2)4.34%
Min Revenue beat(2)0.75%
Max Revenue beat(2)7.92%
Revenue beat(4)4
Avg Revenue beat(4)2.8%
Min Revenue beat(4)0.75%
Max Revenue beat(4)7.92%
Revenue beat(8)8
Avg Revenue beat(8)2.56%
Revenue beat(12)8
Avg Revenue beat(12)-7.79%
Revenue beat(16)10
Avg Revenue beat(16)-10%
PT rev (1m)-0.06%
PT rev (3m)13.06%
EPS NQ rev (1m)-14.95%
EPS NQ rev (3m)-21.16%
EPS NY rev (1m)-16.25%
EPS NY rev (3m)-19.5%
Revenue NQ rev (1m)1.08%
Revenue NQ rev (3m)-1.15%
Revenue NY rev (1m)0.85%
Revenue NY rev (3m)0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 190 | ||
| Fwd PE | 53.67 | ||
| P/S | 1.54 | ||
| P/FCF | 23.49 | ||
| P/OCF | 23.49 | ||
| P/B | 4.22 | ||
| P/tB | 6.79 | ||
| EV/EBITDA | 80.43 |
EPS(TTM)0.12
EY0.53%
EPS(NY)0.42
Fwd EY1.86%
FCF(TTM)0.97
FCFY4.26%
OCF(TTM)0.97
OCFY4.26%
SpS14.77
BVpS5.41
TBVpS3.36
PEG (NY)2.06
PEG (5Y)25.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROCE | 3% | ||
| ROIC | 2% | ||
| ROICexc | 5.87% | ||
| ROICexgc | N/A | ||
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% | ||
| FCFM | 6.57% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score6
Asset Turnover1.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 111.34 | ||
| Cash Conversion | 412.04% | ||
| Profit Quality | 757.69% | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | 4.98 |
F-Score6
WACC9.04%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
EPS Next Y92.08%
EPS Next 2Y96.51%
EPS Next 3Y61.59%
EPS Next 5YN/A
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
Revenue Next Year11.83%
Revenue Next 2Y11.13%
Revenue Next 3Y11.67%
Revenue Next 5Y-0.38%
EBIT growth 1Y45%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year515.6%
EBIT Next 3Y106.09%
EBIT Next 5Y62.91%
FCF growth 1Y202.94%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y202.4%
OCF growth 3Y25.67%
OCF growth 5Y35.01%